Drug intelligence / Profile preview

HXP090

Development stage: Unknown
Lead developer: Haixi New Pharma
Modality: Small Molecules
Administration: Oral

Overview

HXP090 is a small molecule innovative drug (Class 1 chemical drug) developed by Fujian Haixi New Drug Creation Co., Ltd for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The drug was developed using the company's proprietary MultiSel-Opt Platform, which focuses on multi-mechanism synergy by targeting multiple selective protein targets involved in inflammation and immune regulation. HXP090 is designed to address the significant unmet medical need in respiratory fibrosis by leveraging the characteristics of small molecule compounds to achieve therapeutic efficacy through synergistic pathways. As of early 2026, HXP090 is in Phase 2 clinical development in China for the treatment of IPF.

Beyond the preview

Go deeper on HXP090.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXP090.

Explore the full profile